Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Approaches to Increase Early Detection and Positive Biopsy Rate of Nasal Natural Killer/T‐Cell Lymphoma

Approaches to Increase Early Detection and Positive Biopsy Rate of Nasal Natural Killer/T‐Cell... INTRODUCTIONNatural killer/T‐cell lymphoma, nasal type (nasal NKTL), is predominantly found in East Asian and Latin American populations,1,2 accounting for 7%–10% of all nasal non‐Hodgkin lymphoma (NHL) cases worldwide.3 This malignancy primarily affects the nasal cavity, sinuses, and upper respiratory tract.4–6 Nasal NKTL progresses rapidly and was historically referred to as “lethal midline granuloma,”7,8 with poor prognosis and an overall 5‐year survival rate of approximately 29%–40%.9 Early diagnosis and treatment are crucial for improving the survival rates of patients with nasal NKTL. Patients diagnosed at earlier stages according to the Ann Arbor staging system,10 and those treated early with chemotherapy and radiotherapy, have higher 5‐year survival rates than their counterparts.11,12 However, due to the nonspecific nature of the symptoms of nasal NKTL, with lymphoma‐specific systemic “B symptoms” (weight loss >10%, night sweating, fever >38°C) occurring in only 9%–22% of cases,9 early imaging findings may resemble inflammation,13 leading to frequent misdiagnosis as sinusitis.The gold standard for diagnosing nasal NKTL is the pathological diagnosis. However, compared with other malignant tumors, the positive biopsy rate for nasal NKTL is relatively low, with the literature stating that the initial biopsy yields a positive result in only approximately 33% of cases.14 Therefore, identifying diagnostic clues http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Laryngoscope Wiley

Approaches to Increase Early Detection and Positive Biopsy Rate of Nasal Natural Killer/T‐Cell Lymphoma

Download PDF
9 pages

Loading next page...
 
/lp/wiley/approaches-to-increase-early-detection-and-positive-biopsy-rate-of-G4Jx0SVfWS

References (36)

Publisher
Wiley
Copyright
© 2025 The American Laryngological, Rhinological and Otological Society, Inc.
ISSN
0023-852X
eISSN
1531-4995
DOI
10.1002/lary.31914
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONNatural killer/T‐cell lymphoma, nasal type (nasal NKTL), is predominantly found in East Asian and Latin American populations,1,2 accounting for 7%–10% of all nasal non‐Hodgkin lymphoma (NHL) cases worldwide.3 This malignancy primarily affects the nasal cavity, sinuses, and upper respiratory tract.4–6 Nasal NKTL progresses rapidly and was historically referred to as “lethal midline granuloma,”7,8 with poor prognosis and an overall 5‐year survival rate of approximately 29%–40%.9 Early diagnosis and treatment are crucial for improving the survival rates of patients with nasal NKTL. Patients diagnosed at earlier stages according to the Ann Arbor staging system,10 and those treated early with chemotherapy and radiotherapy, have higher 5‐year survival rates than their counterparts.11,12 However, due to the nonspecific nature of the symptoms of nasal NKTL, with lymphoma‐specific systemic “B symptoms” (weight loss >10%, night sweating, fever >38°C) occurring in only 9%–22% of cases,9 early imaging findings may resemble inflammation,13 leading to frequent misdiagnosis as sinusitis.The gold standard for diagnosing nasal NKTL is the pathological diagnosis. However, compared with other malignant tumors, the positive biopsy rate for nasal NKTL is relatively low, with the literature stating that the initial biopsy yields a positive result in only approximately 33% of cases.14 Therefore, identifying diagnostic clues

Journal

The Laryngoscope – Wiley

Published: May 1, 2025

Keywords: ADC measurement; biopsy method; imaging; nasal endoscopy; NK/T‐cell lymphoma

There are no references for this article.